J&J Forges Ahead In Immunology Despite Competitive Dynamics
Executive Summary
The diversified pharma has two NMEs and three sNDAs pending at FDA in immunology, as well as six more anticipated sNDA filings. Immunology Therapeutic Head Susan Dillon told investors why there is still plenty of opportunity for growth in key autoimmune diseases.
You may also be interested in...
J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback
The company said it will pull global regulatory filings for the interleukin-6 inhibitor sirukumab for rheumatoid arthritis after determining regulatory delays would put it too far behind the competition.
J&J Prepares For US Sirukumab Launch After Regaining Rights From GSK
GSK returned US rights to the IL-6 blocker to J&J as it prioritizes its pharma portfolio under the leadership of new CEO Walmsley.
Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
US sales were down 14%, but much of the hit was due to a 2016 price adjustment that was felt across the pharma portfolio, and execs insisted the impact of biosimilars is more moderate than expected.